Core Viewpoint - Health 160 (02656) has seen a significant stock price increase, rising over 256% from its IPO price of 11.89 HKD to a peak of 42.34 HKD, indicating strong market interest and confidence in the company's business model and growth potential [1] Company Overview - Health 160 is an experienced Chinese pharmaceutical and health products wholesaler and a leading provider of digital healthcare integrated services [1] - The company offers a wide range of pharmaceutical health products and comprehensive digital healthcare solutions [1] Digital Healthcare Platform - Health 160 operates an online healthcare service platform that provides digital healthcare solutions, empowering various participants in the healthcare industry [1] - As of March 31, 2025, the platform has connected over 44,600 healthcare institutions, including more than 14,400 hospitals (of which 3,430 are tertiary hospitals) and over 30,200 grassroots healthcare institutions [1] - Among the partnered healthcare institutions, over 6,800 private entities primarily offer consumer medical services such as dental, ophthalmology, and health check-up services through the platform [1]

Core Viewpoint - Health 160 International Limited (Health 160) has successfully listed on the Hong Kong Stock Exchange, with a closing price of 28.22 HKD, reflecting a significant increase of 137.34% from its opening price of 29.98 HKD. The company operates as a wholesaler of pharmaceutical health products and a provider of digital healthcare solutions in China [1]. Group 1: IPO Details - Health 160 issued a total of 33,645,500 shares in its global offering, with 3,364,750 shares allocated for the Hong Kong public offering and 30,280,750 shares for international offering [2]. - The final offer price for the shares was set at 11.89 HKD, resulting in total proceeds of 400 million HKD. After deducting estimated listing expenses of 83.9 million HKD, the net proceeds amounted to 316.1 million HKD [3]. Group 2: Use of Proceeds - The net proceeds from the global offering are intended to be used for expanding healthcare resource coverage, enhancing research and development capabilities, diversifying product and service offerings, exploring strategic partnerships and acquisitions, and for general working capital purposes [3]. Group 3: Financial Performance - Health 160 reported revenues of 525.6 million RMB, 628.6 million RMB, and 620.7 million RMB for the years 2022, 2023, and 2024 respectively, with quarterly revenues of 94.2 million RMB and 100.5 million RMB for the first quarters of 2024 and 2025 [5]. - Despite revenue growth, the company recorded operating losses of 79.2 million RMB, 99.5 million RMB, and 104.6 million RMB for the years 2022, 2023, and 2024, respectively, indicating ongoing challenges in achieving profitability [6]. - The adjusted net losses for the same periods were 118.9 million RMB, 111.2 million RMB, and 108.2 million RMB, with quarterly adjusted net losses of 40.6 million RMB and 17.1 million RMB for the first quarters of 2024 and 2025 [7].

Group 1 - The core viewpoint of the article highlights the successful listing of Health 160 (02656) with a share price of HKD 11.89, raising approximately HKD 316 million from the issuance of 33.6455 million shares [1] - As of the report, the stock price surged by 152.14%, reaching HKD 29.98, with a trading volume of HKD 101 million [1] - Health 160 is described as an experienced wholesaler of pharmaceutical health products and a leading provider of digital healthcare services in China [1] Group 2 - The company offers a wide range of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform that connects various stakeholders in the healthcare industry [1] - As of March 31, 2025, the platform has connected over 44,600 healthcare institutions, including more than 14,400 hospitals and over 30,200 grassroots healthcare institutions [1] Group 3 - Among the partnered healthcare institutions, over 6,800 private entities provide consumer medical services such as dental, ophthalmology, and health check-up services through the platform [1]

Core Viewpoint - Health 160 (02656) was listed on the Hong Kong Stock Exchange on September 17, 2023, opening with a significant increase of 150.97%, resulting in a total market capitalization of HK$100.4 billion [1]. Company Overview - Health 160 is a Chinese wholesale distributor of medical health products and a provider of comprehensive digital healthcare solutions, offering a variety of medical health products and digital healthcare services to clients [2]. - As of March 31, 2025, Health 160 has connected over 44,600 healthcare institutions, including more than 14,400 hospitals and over 30,200 grassroots healthcare institutions [3]. - The company has established partnerships with over 902,300 healthcare professionals, including approximately 46,200 registered doctors, and has a registered user base of 55.2 million individuals [3]. Financial Performance - Health 160's revenue for the years 2022, 2023, and 2024 was RMB 525.646 million, RMB 628.606 million, and RMB 620.682 million, respectively, with corresponding losses of RMB 120.065 million, RMB 106.199 million, and RMB 108.246 million [4]. - In the first quarter of 2025, the company reported revenue of RMB 100.475 million, a year-on-year increase of 6.7%, with a loss of RMB 17.128 million compared to a loss of RMB 40.246 million in the same period the previous year [4][3]. Shareholding Structure - Prior to the IPO, Roning Zheng controlled approximately 33.99% of the voting rights through his wholly-owned companies, LNZ Management Limited and Luo Holdings Limited [5]. - Following the share split and global offering, Roning Zheng is expected to control about 34.08% of the company's issued share capital [5][6]. Leadership - Roning Zheng, the founder, executive director, chairman, and CEO of the group, has over 25 years of industry experience and is responsible for the overall strategy and management of the company [7].